GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Pyxis Oncology PYXS · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.81

+7.74%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Pyxis Oncology — daily PYXS Delayed
Market value
$112.7m
Last close × shares
Volume
3.1m
Shares, 20 Nov 2026

About Pyxis Oncology

From its filings with the US Securities and Exchange Commission

SEC filings

Pyxis Oncology is based in Boston, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PYXS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $13.9m and a net loss of $79.6m. At that date it held total assets of $91.5m and shareholders' equity of $53.4m.

In its own words

Pyxis Oncology is a clinical-stage oncology company advancing a development strategy focused on addressing unmet medical needs in patients with solid tumors with an immediate focus on head and neck squamous cell carcinoma (HNSCC).

Our lead product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational novel antibody-drug conjugate (ADC) that uniquely targets the splice variant of fibronectin, extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the extracellular matrix (ECM) in the tumor microenvironment (TME). EDB+FN is an isoform of fibronectin present in tumors that is negligibly expressed in normal adult tissues and facilitates cancer progression by playing multiple roles including promoting cell proliferation, adhesion, and migration, activating the integrin signaling pathway, stimulating angiogenesis and vascular remodeling, driving epithelial-mesenchymal transition (EMT), and establishing the pre-metastatic niche. We believe EDB+FN is a compelling target for cancer therapeutics as the physiological expression of EDB+FN is very low in healthy adult tissues, yet it is found to be highly expressed in a variety of solid tumors.

Quoted from its 10-K, filed 23 Mar 2026. Read the filing on SEC.gov ↗

More about Pyxis Oncology →

Latest on Pyxis Oncology

Our reporting

Next results

24 Mar 2027

Due on 24 Mar 2027. Analysts expect earnings of -0.22 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Pyxis Oncology's ticker?

Pyxis Oncology trades as PYXS on its US listing, under ISIN US7473241013.

What was Pyxis Oncology's last closing price?

1.81 on 20 Nov 2026. The figure is in USD and is never converted.

When does Pyxis Oncology next report results?

Results are expected on 17 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.